Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 8/20 | 0.41 |
| ▸ | WNT3A | P56704 | 8/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948899 | 0.90 | DRD2 (0.38) | — | |
| SCHEMBL10158650 | 0.81 | CTNNB1 (0.42) | CTNNB1WNT3AHTR1DHTR2CCLK1 | |
| SCHEMBL13861832 | 0.80 | HTR1D (0.40) | CTNNB1WNT3AHTR1DHTR2CCLK1 | |
| SCHEMBL18946020 | 0.80 | CTNNB1 (0.41) | CTNNB1WNT3AHTR1DHTR2CCLK1 | |
| SCHEMBL13035774 | 0.77 | CTNNB1 (0.38) | CTNNB1WNT3AHTR1DHTR2CCLK1 | |
| SCHEMBL13548265 | 0.77 | PKM (0.43) | — | |
| SCHEMBL13092307 | 0.76 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL22792437 | 0.74 | HTR1D (0.39) | CTNNB1WNT3AHTR1DHTR2CCLK1 | |
| SCHEMBL14576619 | 0.74 | CTNNB1 (0.38) | CTNNB1WNT3AHTR1DHTR2CCLK1 | |
| SCHEMBL31168615 | 0.74 | CTNNB1 (0.38) | CTNNB1WNT3AHTR1DHTR2CCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220046-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20130190491-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354429-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2220095-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2220076-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20110118249-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009062285-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062289-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062288-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062308-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190491-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | CTNNB1 4226/4885WNT3A 3673/4885HTR1D 3529/4885 |
| US-20110118249-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, CCNY, RTF1 | CTNNB1 4547/4885WNT3A 4532/4885HTR1D 3500/4885 |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CCNY, RTF2, POLR2E | CTNNB1 3733/4885WNT3A 3881/4885HTR1D 4105/4885 |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, POLR1E | CTNNB1 4012/4885WNT3A 3841/4885HTR1D 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.